Table 3.

Regression analysis for graft failure (N = 383)

	Hazard ratio*	95% CI	P value
Age (mean = 48.6, SD = 13.0)	1.02	0.99–1.04	0.172
Male sex (N = 223)	1.89	0.96–3.72	0.066
Diabetes (N = 117)	1.90	1.01–3.55	0.046
Country of birth			0.108
Foreign-born (N = 75)	Ref	Ref
U.S.-born (N = 150)	2.73	0.61–12.3	0.191
Unidentified (N = 158)	4.16	0.98–17.7	0.053
Rejection (biopsy-confirmed) (N = 18)	2.62	1.14–5.99	0.023
Immune risk			0.143
High (N = 191)	Ref	Ref
Standard (N = 157)	1.38	0.42–4.58	0.598
Low (N = 35)	0.63	0.17–2.34	0.494
Maintenance immunosuppression decreased (N = 12)	0.46	0.06–3.37	0.446
Positive parasite screen† (N = 10)	12.52	0.78–201	0.074
Positive tuberculosis screen‡ (N = 17)	0	N/A	0.998
Living with HIV§ (N = 4)	0	N/A	0.997
High risk EBV (donor+/recipient–) (N = 18)	0	N/A	0.997
High risk CMV (donor+/recipient–) (N = 62)	1.75	0.85–3.57	0.127
High risk toxoplasmosis (donor+/recipient–)ǁ (N = 6)	6.58	0.84–51.70	0.073

CI = confidence interval; CMV = cytomegalovirus; EBV = Epstein–Barr virus; N/A = not applicable; Ref = reference.

Bold indicates a significant P value.

^*There were no events of graft failure among transplant recipients with positive tuberculosis screening, living with HIV, or at high risk for EBV, and thus a hazard ratio could not be calculated for these variables.

^† Includes 100 transplant recipients with strongyloidiasis (N = 95) and/or schistosomiasis (N = 47) screening results. Due to the small number of graft failure events among these transplant recipients, individual hazard ratios for strongyloidiasis and schistosomiasis screening could not be calculated.

^‡ Includes 216 transplant recipients with interferon gamma release assay tuberculosis screening results.

^§ Includes 378 transplant recipients with known HIV status.

^ǁIncludes 304 transplant recipients with known toxoplasmosis status.